• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

SARS-CoV-2:新兴变异株、发病机制、免疫反应、潜在治疗策略和疫苗开发策略的最新趋势。

SARS-CoV-2: Current trends in emerging variants, pathogenesis, immune responses, potential therapeutic, and vaccine development strategies.

机构信息

Department of Virology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.

Department of Anesthesiology, Faculty of Medical Science, Tehran University of Medical Science, Tehran, Iran.

出版信息

Int Immunopharmacol. 2021 Dec;101(Pt A):108232. doi: 10.1016/j.intimp.2021.108232. Epub 2021 Oct 16.

DOI:10.1016/j.intimp.2021.108232
PMID:34673335
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8519814/
Abstract

More than a year after the SARS-CoV-2 pandemic, the Coronavirus disease 19 (COVID-19) is still a major global challenge for scientists to understand the different dimensions of infection and find ways to prevent, treat, and develop a vaccine. On January 30, 2020, the world health organization (WHO) officially announced this new virus as an international health emergency. While many biological and mechanisms of pathogenicity of this virus are still unclear, it seems that cytokine storm resulting from an immune response against the virus is considered the main culprit of the severity of the disease. Despite many global efforts to control the SARS-CoV-2, several problems and challenges have been posed in controlling the COVID-19 infection. These problems include the various mutations, the emergence of variants with high transmissibility, the short period of immunity against the virus, the possibility of reinfection in people improved, lack of specific drugs, and problems in the development of highly sensitive and specific vaccines. In this review, we summarized the results of the current trend and the latest research studies on the characteristics of the structure and genome of the SARS-CoV- 2, new mutations and variants of SARS-CoV-2, pathogenicity, immune response, virus diagnostic tests, potential treatment, and vaccine candidate.

摘要

在 SARS-CoV-2 大流行一年多后,COVID-19 仍然是科学家理解感染不同层面并寻找预防、治疗和开发疫苗方法的主要全球挑战。2020 年 1 月 30 日,世界卫生组织(WHO)正式宣布这种新病毒为国际卫生紧急事件。虽然这种病毒的许多生物学和发病机制仍不清楚,但似乎是针对病毒的免疫反应引起的细胞因子风暴被认为是疾病严重程度的主要罪魁祸首。尽管全球做出了许多控制 SARS-CoV-2 的努力,但在控制 COVID-19 感染方面仍存在一些问题和挑战。这些问题包括各种突变、高传染性变异体的出现、针对病毒的免疫持续时间短、免疫能力提高的人再次感染的可能性、缺乏特效药物以及高度敏感和特异性疫苗开发方面的问题。在这篇综述中,我们总结了 SARS-CoV-2 的结构和基因组特征、SARS-CoV-2 的新突变和变体、发病机制、免疫反应、病毒诊断检测、潜在治疗和疫苗候选物的当前趋势和最新研究结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/231b/8519814/b7be0b88f3fb/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/231b/8519814/c3585a4b83ad/ga1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/231b/8519814/b0a32c5d0990/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/231b/8519814/b7be0b88f3fb/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/231b/8519814/c3585a4b83ad/ga1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/231b/8519814/b0a32c5d0990/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/231b/8519814/b7be0b88f3fb/gr2_lrg.jpg

相似文献

1
SARS-CoV-2: Current trends in emerging variants, pathogenesis, immune responses, potential therapeutic, and vaccine development strategies.SARS-CoV-2:新兴变异株、发病机制、免疫反应、潜在治疗策略和疫苗开发策略的最新趋势。
Int Immunopharmacol. 2021 Dec;101(Pt A):108232. doi: 10.1016/j.intimp.2021.108232. Epub 2021 Oct 16.
2
COVID-19: Structural Considerations for Virus Pathogenesis, Therapeutic Strategies and Vaccine Design in the Novel SARS-CoV-2 Variants Era.新型 SARS-CoV-2 变异株时代的病毒发病机制、治疗策略和疫苗设计的结构考虑因素:COVID-19
Mol Biotechnol. 2021 Oct;63(10):885-897. doi: 10.1007/s12033-021-00353-4. Epub 2021 Jun 18.
3
The Current Status and Challenges in the Development of Vaccines and Drugs against Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2).严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)疫苗和药物研发的现状与挑战。
Biomed Res Int. 2021 Jun 1;2021:8160860. doi: 10.1155/2021/8160860. eCollection 2021.
4
mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status.mRNA 疫苗诱导的 T 细胞对 SARS-CoV-2 关切变异株的反应完全相同,但根据先前的感染状态,其持久性和归巢特性存在差异。
Elife. 2021 Oct 12;10:e72619. doi: 10.7554/eLife.72619.
5
SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies.SARS-CoV-2 变体和 COVID-19 疫苗:当前的挑战与未来策略。
Int Rev Immunol. 2023;42(6):393-414. doi: 10.1080/08830185.2022.2079642. Epub 2022 May 28.
6
Immune Evasive Effects of SARS-CoV-2 Variants to COVID-19 Emergency Used Vaccines.新冠病毒变异株对新冠疫情紧急使用疫苗的免疫逃逸作用
Front Immunol. 2021 Nov 22;12:771242. doi: 10.3389/fimmu.2021.771242. eCollection 2021.
7
Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update.SARS-CoV-2/COVID-19 大流行管理的潜在治疗靶点和疫苗开发:近期进展综述。
Front Immunol. 2021 Jun 30;12:658519. doi: 10.3389/fimmu.2021.658519. eCollection 2021.
8
A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.一种基于三聚体 RBD 的马赛克型 COVID-19 疫苗候选物可诱导针对奥密克戎和其他 SARS-CoV-2 变体的强大中和作用。
Elife. 2022 Aug 25;11:e78633. doi: 10.7554/eLife.78633.
9
Potential SARS-CoV-2 vaccines: Concept, progress, and challenges.潜在的 SARS-CoV-2 疫苗:概念、进展和挑战。
Int Immunopharmacol. 2021 Aug;97:107622. doi: 10.1016/j.intimp.2021.107622. Epub 2021 Mar 29.
10
SARS-CoV-2 Infection: New Molecular, Phylogenetic, and Pathogenetic Insights. Efficacy of Current Vaccines and the Potential Risk of Variants.SARS-CoV-2 感染:新的分子、系统发生和发病机制见解。当前疫苗的功效和变异的潜在风险。
Viruses. 2021 Aug 25;13(9):1687. doi: 10.3390/v13091687.

引用本文的文献

1
Timing of total joint arthroplasty post-COVID-19: an evaluation of the optimal window to minimize perioperative risks.新冠病毒感染后全关节置换术的时机:对使围手术期风险最小化的最佳窗口期的评估
Arthroplasty. 2024 Oct 4;6(1):53. doi: 10.1186/s42836-024-00275-x.
2
Synergistic Effect of Maternal Micronutrient Supplementation on ORFV DNA Vaccine Immune Response in a Pregnant Model.孕期模型中母体补充微量营养素对羊口疮病毒DNA疫苗免疫反应的协同作用
Biol Trace Elem Res. 2025 Mar;203(3):1582-1599. doi: 10.1007/s12011-024-04263-9. Epub 2024 Jun 14.
3
Automated breast tumor ultrasound image segmentation with hybrid UNet and classification using fine-tuned CNN model.

本文引用的文献

1
Model-based estimation of transmissibility and reinfection of SARS-CoV-2 P.1 variant.基于模型对新冠病毒P.1变体的传播性和再感染情况的估计。
Commun Med (Lond). 2021 Nov 15;1:48. doi: 10.1038/s43856-021-00048-6. eCollection 2021.
2
On the origin and continuing evolution of SARS-CoV-2.关于严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的起源及持续进化
Natl Sci Rev. 2020 Jun;7(6):1012-1023. doi: 10.1093/nsr/nwaa036. Epub 2020 Mar 3.
3
INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants.
基于混合UNet的乳腺肿瘤超声图像自动分割及使用微调卷积神经网络模型的分类
Heliyon. 2023 Oct 21;9(11):e21369. doi: 10.1016/j.heliyon.2023.e21369. eCollection 2023 Nov.
4
Association between serologically confirmed COVID-19 infection and cognitive functioning in community dwelling older adults.血清学确诊的2019冠状病毒病感染与社区居住老年人认知功能之间的关联。
Front Neurol. 2023 Mar 21;14:1093852. doi: 10.3389/fneur.2023.1093852. eCollection 2023.
5
Dermatological Manifestations in COVID-19: A Case Study of SARS-CoV-2 Infection in a Genetic Thrombophilic Patient with Mthfr Mutation.新型冠状病毒肺炎的皮肤表现:一例伴有亚甲基四氢叶酸还原酶(Mthfr)突变的遗传性易栓症患者感染严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的病例研究
Pathogens. 2023 Mar 10;12(3):438. doi: 10.3390/pathogens12030438.
6
The protection quest is a primary key to sharing the neutralizing antibody response to cover against all emerging VOCs based on BIV1-CovIran studies.基于BIV1-CovIran研究,寻求保护是共享中和抗体反应以抵御所有新出现的变异株的关键。
Heliyon. 2023 Mar;9(3):e14108. doi: 10.1016/j.heliyon.2023.e14108. Epub 2023 Feb 26.
7
Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and strategies.全球新兴的 SARS-CoV-2 奥密克戎变异株:影响、挑战与策略。
J Infect Public Health. 2023 Jan;16(1):4-14. doi: 10.1016/j.jiph.2022.11.024. Epub 2022 Nov 19.
8
The Impact of Immune-Modifying Treatments for Skin Diseases on the Immune Response to COVID-19 Vaccines: a Narrative Review.皮肤病免疫调节治疗对COVID-19疫苗免疫反应的影响:一项叙述性综述。
Curr Dermatol Rep. 2022;11(4):263-288. doi: 10.1007/s13671-022-00376-3. Epub 2022 Oct 25.
9
A Bivalent COVID-19 Vaccine Based on Alpha and Beta Variants Elicits Potent and Broad Immune Responses in Mice against SARS-CoV-2 Variants.一种基于α和β变体的二价新冠疫苗在小鼠体内引发针对新冠病毒变体的强效和广泛免疫反应。
Vaccines (Basel). 2022 Apr 29;10(5):702. doi: 10.3390/vaccines10050702.
10
Strategies to tackle SARS-CoV-2 Mu, a newly classified variant of interest likely to resist currently available COVID-19 vaccines.应对 SARS-CoV-2 Mu 的策略,Mu 是一种新分类的值得关注的变异株,可能对目前可用的 COVID-19 疫苗产生耐药性。
Hum Vaccin Immunother. 2022 Dec 31;18(1):2027197. doi: 10.1080/21645515.2022.2027197. Epub 2022 Feb 16.
INO-4800 DNA疫苗可诱导针对全球新冠病毒变异株的中和抗体和T细胞活性。
NPJ Vaccines. 2021 Oct 14;6(1):121. doi: 10.1038/s41541-021-00384-7.
4
Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273.接种BNT162b2和mRNA-1273后新型冠状病毒2型抗体反应的比较
JAMA. 2021 Oct 19;326(15):1533-1535. doi: 10.1001/jama.2021.15125.
5
Pre-activated antiviral innate immunity in the upper airways controls early SARS-CoV-2 infection in children.上呼吸道预先激活的抗病毒先天免疫可控制儿童早期 SARS-CoV-2 感染。
Nat Biotechnol. 2022 Mar;40(3):319-324. doi: 10.1038/s41587-021-01037-9. Epub 2021 Aug 18.
6
Investigating the Links Between Vaccination Against COVID-19 and Public Attitudes Toward Protective Countermeasures: Implications for Public Health.探讨 COVID-19 疫苗接种与公众对防护措施态度之间的关联:对公共卫生的启示。
Front Public Health. 2021 Jul 21;9:702699. doi: 10.3389/fpubh.2021.702699. eCollection 2021.
7
COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies.新型冠状病毒肺炎:揭开新兴的严重急性呼吸系统综合征冠状病毒 2 变种、疫苗和治疗策略的神秘面纱。
Biomolecules. 2021 Jul 6;11(7):993. doi: 10.3390/biom11070993.
8
Modelling conformational state dynamics and its role on infection for SARS-CoV-2 Spike protein variants.模拟构象状态动力学及其在 SARS-CoV-2 刺突蛋白变体感染中的作用。
PLoS Comput Biol. 2021 Aug 5;17(8):e1009286. doi: 10.1371/journal.pcbi.1009286. eCollection 2021 Aug.
9
Remdesivir for the treatment of COVID-19.瑞德西韦用于治疗新型冠状病毒肺炎。
Cochrane Database Syst Rev. 2021 Aug 5;8(8):CD014962. doi: 10.1002/14651858.CD014962.
10
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.Covid-19 疫苗对 B.1.617.2(德尔塔)变异株的有效性。
N Engl J Med. 2021 Aug 12;385(7):585-594. doi: 10.1056/NEJMoa2108891. Epub 2021 Jul 21.